(R)-Roscovitine (Synonyms: Seliciclib; CYC202)

目录号: HY-30237 纯度: 99.84%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

(R)-Roscovitine (Seliciclib) 是一种有效的，具有口服活性的，选择性的 CDKs 抑制剂，抑制 CDK5，Cdc2 和 CDK2 的 IC₅₀ 分别为0.2 μM，0.65 μM，0.7 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(R)-Roscovitine Chemical Structure

CAS No. : 186692-46-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
1 mg	￥250	In-stock
5 mg	￥500	In-stock
10 mg	￥880	In-stock
50 mg	￥1900	In-stock
100 mg	￥2900	In-stock
200 mg	￥4900	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of (R)-Roscovitine:

(S)-Roscovitine 询价
(R)-Roscovitine-d₇ 询价

MCE 顾客使用本产品发表的 31 篇科研文献

: (R)-Roscovitine purchased from MCE. Usage Cited in: Neuroreport. 2018 Mar 7;29(4):241-246. [Abstract]; R-E 235da1 exposure increases Cdk5 activity. Protein expression levels of P-histone H1 and Cdk5. P-histone H1 levels represent the activity of Cdk5. Bands for Cdk5 are the input. R-E 235da1 exposure increased Cdk5 activity.

(R)-Roscovitine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 CDK 亚型特异性产品:

查看所有亚型

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

(R)-Roscovitine (Seliciclib) is an orally bioavailable and selective CDKs inhibitor with IC₅₀s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.

IC₅₀ & Target^[1]

cdc2/cyclin B

0.65 μM (IC₅₀)

cdk2/cyclin A

0.7 μM (IC₅₀)

Cdk2/cyclin E2

0.7 μM (IC₅₀)

CDK5/p35

0.16 μM (IC₅₀)

GST-erk1

30 μM (IC₅₀)

erk1

34 μM (IC₅₀)

erk2

14 μM (IC₅₀)

IR tyrosine kinase

70 μM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
786-0	GI₅₀	25.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
A2780	GI₅₀	12.5 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of cisplatin-resistant human A2780 cells after 96 hrs by sulforhodamine B assay Growth inhibition of cisplatin-resistant human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
A2780	GI₅₀	4.45 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of cisplatin-susceptible human A2780 cells after 96 hrs by sulforhodamine B assay Growth inhibition of cisplatin-susceptible human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
A-375	IC₅₀	11.79 μM Compound: Roscovitine	Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
A498	GI₅₀	50.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
A549	IC₅₀	> 10 μM Compound: Roscovitine	Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay	[PMID: 31272794]
A549	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
A549	IC₅₀	14.14 μM Compound: (R)-roscovitine	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 23036956]
A549	IC₅₀	14.7 μM Compound: Roscovitine	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 20361800]
A549	GI₅₀	15 μM Compound: Roscovitine	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
A549	IC₅₀	2.18 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23623491]
ACHN	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay	[PMID: 19128055]
ACHN	IC₅₀	2.88 μM Compound: 1	Cytotoxicity against human ACHN cells after 48 hrs by MTT assay Cytotoxicity against human ACHN cells after 48 hrs by MTT assay	[PMID: 23623491]
ASPC1	IC₅₀	17767 nM Compound: Roscovitine	Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
BXPC-3	IC₅₀	15284 nM Compound: Roscovitine	Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
Caco-2	IC₅₀	10 μM Compound: Roscovitine	Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Caco-2	IC₅₀	10 μM Compound: Roscovitin	Cytotoxicity against human Caco2 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis Cytotoxicity against human Caco2 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis	[PMID: 21944287]
Caco-2	IC₅₀	12.9 μM Compound: Rosco	Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
Caco-2	IC₅₀	14 μM Compound: Roscovitine	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Caco-2	IC₅₀	17 μM Compound: Roscovitine	Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Caco-2	IC₅₀	3 μM Compound: Roscovitine	Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 3342 staining analysis Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 3342 staining analysis	[PMID: 27019296]
Caco-2	IC₅₀	3 μM Compound: Roscovitine	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay	[PMID: 26142492]
Caco-2	IC₅₀	5 μM Compound: Roscovitine	Antiproliferative activity against human Caco2 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay Antiproliferative activity against human Caco2 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay	[PMID: 23063566]
Caco-2	IC₅₀	6 μM Compound: Roscovitine	Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis	[PMID: 19665384]
CAKI-1	GI₅₀	6.3 μM Compound: (R)-roscovitine	Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
CAL-148	IC₅₀	> 10 μM Compound: Roscovitine	Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay	[PMID: 31272794]
CCRF-CEM	GI₅₀	> 100 μM Compound: (R)-roscovitine	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay	[PMID: 19128055]
CCRF-CEM	IC₅₀	16.3 μM Compound: Roscovitine	Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
CH1	GI₅₀	3.25 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of doxorubicin-susceptible human CH1 cells after 96 hrs by sulforhodamine B assay Growth inhibition of doxorubicin-susceptible human CH1 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
CH1	GI₅₀	5.4 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of doxorubicin-resistant human CH1 cells after 96 hrs by sulforhodamine B assay Growth inhibition of doxorubicin-resistant human CH1 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
COLO 205	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
COLO 205	GI₅₀	24.9 μM Compound: Roscovitine	Antiproliferative activity against human COLO205 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human COLO205 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
DU-145	IC₅₀	1.9 μM Compound: 1	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23623491]
DU-145	GI₅₀	15.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
EKVX	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay	[PMID: 19128055]
Epithelial cell	IC₅₀	25 μM Compound: K00020, roscovitine	Growth inhibition of human renal epithelial cells after 72 hrs by TUNEL assay Growth inhibition of human renal epithelial cells after 72 hrs by TUNEL assay	[PMID: 18077363]
Fibroblast	IC₅₀	> 20 μM Compound: Rosco	Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
Fibroblast	IC₅₀	> 25 μM Compound: Roscovitin	Cytotoxicity against human fibroblast cells after 48 hrs by Hoechst-33342 staining-based imaging analysis Cytotoxicity against human fibroblast cells after 48 hrs by Hoechst-33342 staining-based imaging analysis	[PMID: 21944287]
Fibroblast	IC₅₀	> 25 μM Compound: Roscovitine	Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis	[PMID: 19665384]
Fibroblast	IC₅₀	12 μM Compound: Roscovitine	Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Fibroblast	IC₅₀	15 μM Compound: Roscovitine	Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Fibroblast	IC₅₀	6 μM Compound: Roscovitine	Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
G-361	IC₅₀	20.8 μM Compound: Seliciclib; L2	Cytotoxicity against human G361 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method Cytotoxicity against human G361 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method	[PMID: 26741853]
G-361	IC₅₀	22.4 μM Compound: Roscov	Cytotoxicity against human G361 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay Cytotoxicity against human G361 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 26851505]
G-361	IC₅₀	22.4 μM Compound: Roscovitine	Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
G-361	IC₅₀	22.4 μM Compound: roscovitine, CYC202, seliciclib	Cytotoxicity against human G361 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay Cytotoxicity against human G361 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay	[PMID: 23829517]
Granta-519	IC₅₀	25 μM Compound: K00020, roscovitine	Growth inhibition of human Granta519 cells after 72 hrs by TUNEL assay Growth inhibition of human Granta519 cells after 72 hrs by TUNEL assay	[PMID: 18077363]
HaCaT	IC₅₀	12 μM Compound: Roscovitine	Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HaCaT	IC₅₀	16.7 μM Compound: Rosco	Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HCC 2998	GI₅₀	31.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HCT-116	IC₅₀	14.4 μM Compound: Roscovitine	Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HCT-116	IC₅₀	14.4 μM Compound: roscovitine, CYC202, seliciclib	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay	[PMID: 23829517]
HCT-116	IC₅₀	14.42 μM Compound: Roscov	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 26851505]
HCT-116	GI₅₀	15.5 μM Compound: Roscovitine	Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
HCT-116	IC₅₀	15.54 μM Compound: Roscovitine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32773088]
HCT-116	IC₅₀	16.38 μM Compound: (R)-roscovitine	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 23036956]
HCT-116	IC₅₀	2 μM Compound: Roscovitine	Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 3342 staining analysis Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 3342 staining analysis	[PMID: 27019296]
HCT-116	IC₅₀	2 μM Compound: Roscovitine	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay	[PMID: 26142492]
HCT-116	IC₅₀	5 μM Compound: Roscovitine	Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis	[PMID: 19665384]
HCT-116	GI₅₀	5.01 μM Compound: (R)-roscovitine	Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HCT-116	GI₅₀	5.05 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
HCT-116	IC₅₀	6.76 μM Compound: Roscovitine	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
HCT-116	IC₅₀	7 μM Compound: Roscovitine	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay	[PMID: 23063566]
HCT-116	IC₅₀	8 μM Compound: Rosco	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
HCT-116	IC₅₀	8 μM Compound: Roscovitin	Cytotoxicity against human HCT116 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis Cytotoxicity against human HCT116 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis	[PMID: 21944287]
HCT-116	IC₅₀	9 μM Compound: Roscovitine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
HCT-116	IC₅₀	9 μM Compound: Roscovitine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
HCT-116	IC₅₀	9 μM Compound: Roscovitine	Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HCT-15	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HEK293	IC₅₀	23.4 μM Compound: Roscovitine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	46.7 μM Compound: 8a, (R)-roscovitine	Antiproliferative activity against HEK293 cells assessed as survival after 48 hrs by MTS reduction assay Antiproliferative activity against HEK293 cells assessed as survival after 48 hrs by MTS reduction assay	[PMID: 18698753]
HEK293	IC₅₀	48.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human HEK293 cells after 48 hrs by MTS reduction assay Antiproliferative activity against human HEK293 cells after 48 hrs by MTS reduction assay	[PMID: 19128055]
HeLa	IC₅₀	1.81 μM Compound: 1	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23623491]
HeLa	IC₅₀	11.21 μM Compound: Roscovitine	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
HeLa	IC₅₀	2.2 μM Compound: Roscovitine	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 36325400]
HeLa	IC₅₀	28.6 μM Compound: roscovitine, CYC202, seliciclib	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay	[PMID: 23829517]
HeLa S3	GI₅₀	20 μM Compound: 2	Antiproliferative activity against human HeLaS3 cells by sulforhodamine B assay Antiproliferative activity against human HeLaS3 cells by sulforhodamine B assay	[PMID: 19846305]
Hep 3B2	IC₅₀	9 μM Compound: Roscovitine	Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
HepG2	IC₅₀	15.47 μM Compound: (R)-roscovitine	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 23036956]
HepG2	IC₅₀	15.76 μM Compound: Roscovitine	Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay	[PMID: 31272794]
HepG2	GI₅₀	25.9 μM Compound: Roscovitine	Antiproliferative activity against human HepG2 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
HepG2	IC₅₀	8.53 μM Compound: Roscovitine	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
HL-60(TB)	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HOP-62	GI₅₀	25.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HOP-92	GI₅₀	50.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HOS	IC₅₀	24.3 μM Compound: Roscovitine	Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
HOS	IC₅₀	24.3 μM Compound: roscovitine, CYC202, seliciclib	Cytotoxicity against human HOS cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay Cytotoxicity against human HOS cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay	[PMID: 23829517]
Hs-578T	GI₅₀	12.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HT-1080	IC₅₀	16.8 μM Compound: Roscovitine	Antiproliferative activity against human HT1080 cells after 3 days by SRB assay Antiproliferative activity against human HT1080 cells after 3 days by SRB assay	[PMID: 20361800]
HT-1080	IC₅₀	9.62 μM Compound: (R)-roscovitine	Cytotoxicity against human HT1080 cells after 48 hrs by SRB assay Cytotoxicity against human HT1080 cells after 48 hrs by SRB assay	[PMID: 23036956]
HT-29	IC₅₀	11.63 μM Compound: (R)-roscovitine	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 23036956]
HT-29	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
HT-29	GI₅₀	6.4 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of human HT-29 cells after 96 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
Huh-7	IC₅₀	10 μM Compound: Roscovitin	Cytotoxicity against human HuH7 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis Cytotoxicity against human HuH7 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis	[PMID: 21944287]
Huh-7	IC₅₀	12 μM Compound: Roscovitine	Antiproliferative activity against human HuH7 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay Antiproliferative activity against human HuH7 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay	[PMID: 23063566]
Huh-7	IC₅₀	14 μM Compound: Roscovitine	Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Huh-7	IC₅₀	15.4 μM Compound: Rosco	Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
Huh-7	IC₅₀	20 μM Compound: Roscovitine	Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Huh-7	IC₅₀	5 μM Compound: Roscovitine	Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 3342 staining analysis Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 3342 staining analysis	[PMID: 27019296]
Huh-7	IC₅₀	5 μM Compound: Roscovitine	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay	[PMID: 26142492]
Huh-7	IC₅₀	5 μM Compound: Roscovitine	Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis	[PMID: 19665384]
Huh-7	IC₅₀	9 μM Compound: Roscovitine	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
HUVEC	GI₅₀	3.7 μM Compound: Roscovitine	Antiproliferative activity against human HUVEC cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HUVEC cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
IGROV-1	GI₅₀	6.3 μM Compound: (R)-roscovitine	Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
IMR-32	IC₅₀	17 μM Compound: (R)-Roscovitine; Roscovitine	Antiproliferative activity against human IMR32 cells after 2 days by XTT assay Antiproliferative activity against human IMR32 cells after 2 days by XTT assay	[PMID: 30199702]
K562	IC₅₀	> 20 μM Compound: Roscovitine	Antiproliferative activity against human K562 cells after 3 days by SRB assay Antiproliferative activity against human K562 cells after 3 days by SRB assay	[PMID: 20361800]
K562	IC₅₀	30.9 μM Compound: Seliciclib; L2	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method	[PMID: 26741853]
K562	IC₅₀	42 μM Compound: roscovitine	Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay	[PMID: 25757603]
K562	IC₅₀	45.5 μM Compound: Roscov	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 26851505]
K562	IC₅₀	45.5 μM Compound: Roscovitine	Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
K562	IC₅₀	45.5 μM Compound: Roscovitine	Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay	[PMID: 23981532]
K562	IC₅₀	45.5 μM Compound: roscovitine, CYC202, seliciclib	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay	[PMID: 23829517]
K562	GI₅₀	50.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
KB	IC₅₀	24.6 μM Compound: Roscovitine	Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
KB	IC₅₀	30.1 μM Compound: Roscovitine	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 20361800]
KM12	GI₅₀	15 μM Compound: 1, alphaR-1, CYC202, Seliciclib, R-roscovitine	Growth inhibition of human KM12 cells after 96 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells after 96 hrs by sulforhodamine B assay	[PMID: 21982796]
KM12	GI₅₀	5.01 μM Compound: (R)-roscovitine	Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
L02	IC₅₀	20.48 μM Compound: (R)-roscovitine	Cytotoxicity against human L02 cells after 48 hrs by SRB assay Cytotoxicity against human L02 cells after 48 hrs by SRB assay	[PMID: 23036956]
LOX IMVI	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay	[PMID: 19128055]
LP-1	IC₅₀	12.68 μM Compound: CYC202, R-roscovitine	Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
M14	GI₅₀	25.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
Malme-3M	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay	[PMID: 19128055]
MCF-10A	GI₅₀	16.3 μM Compound: Roscovitine	Antiproliferative activity against human MCF10A cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF10A cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
MCF7	IC₅₀	10.2 μM Compound: Rosco	Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MCF7	IC₅₀	11 μM Compound: roscovitine	Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay	[PMID: 25757603]
MCF7	IC₅₀	12.22 μM Compound: (R)-roscovitine	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 23036956]
MCF7	IC₅₀	12.25 μM Compound: Roscov	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 26851505]
MCF7	IC₅₀	12.3 μM Compound: Roscovitine	Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay	[PMID: 22770608]
MCF7	IC₅₀	12.3 μM Compound: Roscovitine	Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay	[PMID: 23981532]
MCF7	IC₅₀	12.3 μM Compound: roscovitine, CYC202, seliciclib	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay	[PMID: 23829517]
MCF7	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
MCF7	IC₅₀	14.7 μM Compound: Roscovitine	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 20361800]
MCF7	IC₅₀	19.6 μM Compound: Roscovitine	Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MCF7	IC₅₀	20.2 μM Compound: Roscovitine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by calcien AM dye based fluorescence analysis Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by calcien AM dye based fluorescence analysis	[PMID: 23399722]
MCF7	IC₅₀	27.2 μM Compound: Seliciclib; L2	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method	[PMID: 26741853]
MCF7	IC₅₀	3.98 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23623491]
MCF7	IC₅₀	55.01 μM Compound: R-Roscovitine	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by WST-1 assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by WST-1 assay	[PMID: 21440449]
MCF7	GI₅₀	7.8 μM Compound: Roscovitine	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
MCF7	IC₅₀	9 μM Compound: Roscovitine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
MCF7	IC₅₀	9 μM Compound: Roscovitine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
MDA-MB-231	IC₅₀	12 μM Compound: Roscovitine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
MDA-MB-231	IC₅₀	12 μM Compound: Roscovitine	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay	[PMID: 23063566]
MDA-MB-231	IC₅₀	15 μM Compound: Roscovitine	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
MDA-MB-231	IC₅₀	15 μM Compound: Roscovitin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis	[PMID: 21944287]
MDA-MB-231	IC₅₀	16.8 μM Compound: Rosco	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
MDA-MB-231	IC₅₀	17 μM Compound: Roscovitine	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
MDA-MB-231	GI₅₀	22.6 μM Compound: Roscovitine	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
MDA-MB-231	IC₅₀	3 μM Compound: Roscovitine	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 3342 staining analysis Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 3342 staining analysis	[PMID: 27019296]
MDA-MB-231	IC₅₀	3 μM Compound: Roscovitine	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay	[PMID: 26142492]
MDA-MB-231	GI₅₀	39.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
MDA-MB-231	IC₅₀	54.64 μM Compound: R-Roscovitine	Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by WST-1 assay Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by WST-1 assay	[PMID: 21440449]
MDA-MB-435	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
MDA-MB-468	IC₅₀	18 μM Compound: Roscovitine	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
MIA PaCa-2	IC₅₀	18214 nM Compound: Roscovitine	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
MKN-45	IC₅₀	7.6 μM Compound: Roscovitine	Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
MOLT-4	GI₅₀	25.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI/ADR-RES	GI₅₀	6.3 μM Compound: (R)-roscovitine	Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI-H226	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI-H23	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI-H322M	GI₅₀	31.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI-H460	IC₅₀	11.6 μM Compound: Roscovitine	Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
NCI-H460	IC₅₀	11.9 μM Compound: Roscovitine	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 32361064]
NCI-H460	GI₅₀	25.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI-H522	GI₅₀	15.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
NCI-H727	IC₅₀	> 20 μM Compound: Rosco	Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
NCI-H727	IC₅₀	20 μM Compound: Roscovitine	Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
NCI-H727	IC₅₀	20 μM Compound: Roscovitine	Antiproliferative activity against human NCI-H727 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay Antiproliferative activity against human NCI-H727 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay	[PMID: 23063566]
NCI-H727	IC₅₀	28 μM Compound: Roscovitine	Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
NCI-H727	IC₅₀	4 μM Compound: Roscovitine	Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 3342 staining analysis Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 3342 staining analysis	[PMID: 27019296]
NCI-H727	IC₅₀	4 μM Compound: Roscovitine	Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay	[PMID: 26142492]
NCI-H929	IC₅₀	8.84 μM Compound: CYC202, R-roscovitine	Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
Non-small cell lung cancer cells	GI₅₀	23.6 μM Compound: Roscovitine	Anticancer activity against human Non-small cell lung cancer cell line assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Non-small cell lung cancer cell line assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Oocyte	IC₅₀	0.65 nM Compound: 3; CYC202	Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis	[PMID: 35485642]
Oocyte	IC₅₀	650 nM Compound: 2	Inhibition of starfish oocyte CDK1 using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by radiometric scintillation assay Inhibition of starfish oocyte CDK1 using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by radiometric scintillation assay	[PMID: 35235745]
OPM-2	IC₅₀	18.46 μM Compound: CYC202, R-roscovitine	Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
OVCAR-3	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
OVCAR-3	IC₅₀	37 μM Compound: (R)-Roscovitine; Roscovitine	Antiproliferative activity against human OVCAR3 cells after 2 days by XTT assay Antiproliferative activity against human OVCAR3 cells after 2 days by XTT assay	[PMID: 30199702]
OVCAR-4	GI₅₀	31.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
OVCAR-5	GI₅₀	39.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
Panel breast cells	GI₅₀	22.7 μM Compound: Roscovitine	Anticancer activity against human Panel breast (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel breast (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel CNS (Carcinoma cell lines)	GI₅₀	24.7 μM Compound: Roscovitine	Anticancer activity against human Panel CNS (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel CNS (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel colon cells	GI₅₀	24.8 μM Compound: Roscovitine	Anticancer activity against human Panel colon (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel colon (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel leukemia cells	GI₅₀	37.5 μM Compound: Roscovitine	Anticancer activity against human Panel leukemia (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel leukemia (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel melanoma cells	GI₅₀	14.8 μM Compound: Roscovitine	Anticancer activity against human Panel melanoma (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel melanoma (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel ovarian cells	GI₅₀	29.3 μM Compound: Roscovitine	Anticancer activity against human Panel ovarian (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel ovarian (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel prostate cells	GI₅₀	17.9 μM Compound: Roscovitine	Anticancer activity against human Panel prostate (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel prostate (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
Panel renal cells	GI₅₀	24.9 μM Compound: Roscovitine	Anticancer activity against human Panel renal (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay Anticancer activity against human Panel renal (Carcinoma cell lines) assessed as cell growth inhibition incubated for 48 hrs by Sulphorhodamine B assay	[PMID: 27744184]
PC-3	IC₅₀	10 μM Compound: Roscovitine	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
PC-3	IC₅₀	10 μM Compound: Roscovitine	Antiproliferative activity against human PC3 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay Antiproliferative activity against human PC3 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay	[PMID: 23063566]
PC-3	IC₅₀	11 μM Compound: Roscovitine	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
PC-3	IC₅₀	12 μM Compound: Roscovitine	Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
PC-3	IC₅₀	16.5 μM Compound: Rosco	Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
PC-3	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
PC-3	IC₅₀	2 μM Compound: Roscovitine	Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 3342 staining analysis Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 3342 staining analysis	[PMID: 27019296]
PC-3	IC₅₀	2 μM Compound: Roscovitine	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay	[PMID: 26142492]
PC-3	GI₅₀	25.2 μM Compound: Roscovitine	Antiproliferative activity against human PC3 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
PC-3	IC₅₀	8 μM Compound: Roscovitin	Cytotoxicity against human PC3 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis Cytotoxicity against human PC3 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis	[PMID: 21944287]
PC-3	IC₅₀	8 μM Compound: Roscovitine	Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis	[PMID: 19665384]
RL	IC₅₀	0.9 μM Compound: Rosco	Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay	[PMID: 28214231]
RPMI-8226	IC₅₀	19.5 μM Compound: CYC202, R-roscovitine	Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
RXF 393	GI₅₀	5 μM Compound: (R)-roscovitine	Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SAOS-2	GI₅₀	13.9 μM Compound: Roscovitine	Antiproliferative activity against human Saos2 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human Saos2 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
Sf21	IC₅₀	0.5 μM Compound: Roscovitine	Inhibition of CDK2/cyclin A expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay Inhibition of CDK2/cyclin A expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay	[PMID: 22000924]
Sf21	IC₅₀	0.5 μM Compound: Roscovitine	Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP	[PMID: 23933045]
Sf21	IC₅₀	15 μM Compound: Roscovitine	Inhibition of CDK4/cyclin D expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay Inhibition of CDK4/cyclin D expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay	[PMID: 22000924]
Sf21	IC₅₀	193 nM Compound: Roscovitine	Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31272794]
SF-268	GI₅₀	19.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SF-268	IC₅₀	8.8 μM Compound: Roscovitine	Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay	[PMID: 25988923]
SF-295	GI₅₀	25.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SF-539	GI₅₀	15.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
Sf9	IC₅₀	> 100 μM Compound: Roscovitine	Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP	[PMID: 24681986]
Sf9	IC₅₀	0.1 μM Compound: 24, CYC202, Seliciclib	Inhibition of His-6-tagged recombinant human CDK2/cyclinE expressed in baculovirus-infected sf9 cells using histone H1 as substrate after 10 mins by liquid scintillation counting in presence of [gamma-32P]ATP Inhibition of His-6-tagged recombinant human CDK2/cyclinE expressed in baculovirus-infected sf9 cells using histone H1 as substrate after 10 mins by liquid scintillation counting in presence of [gamma-32P]ATP	[PMID: 24417566]
Sf9	IC₅₀	0.1 μM Compound: Roscovitine	Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP	[PMID: 24681986]
Sf9	IC₅₀	0.158 μM Compound: Roscov	Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP	[PMID: 26851505]
Sf9	IC₅₀	0.2 μM Compound: Seliciclib; L2	Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP	[PMID: 26741853]
Sf9	IC₅₀	0.27 μM Compound: Roscovitine	Inhibition of recombinant full length N-terminal GST tagged human CDK5/p25 expressed in baculovirus infected sf9 cells using histone H1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay Inhibition of recombinant full length N-terminal GST tagged human CDK5/p25 expressed in baculovirus infected sf9 cells using histone H1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay	[PMID: 31098000]
Sf9	IC₅₀	0.49 μM Compound: 24, CYC202, Seliciclib	Inhibition of His-6-tagged recombinant human CDK7/cyclinH expressed in baculovirus-infected sf9 cells using biotinyl-Ahx-(YSPTSPS)4 as substrate after 45 mins by liquid scintillation counting in presence of [gamma-32P]ATP Inhibition of His-6-tagged recombinant human CDK7/cyclinH expressed in baculovirus-infected sf9 cells using biotinyl-Ahx-(YSPTSPS)4 as substrate after 45 mins by liquid scintillation counting in presence of [gamma-32P]ATP	[PMID: 24417566]
Sf9	IC₅₀	0.7 μM Compound: Roscovitine	Inhibition of GST-fused CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP Inhibition of GST-fused CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP	10.1007/s00044-009-9233-5
Sf9	IC₅₀	0.7 μM Compound: Roscovitine	Inhibition of GST-fused CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP Inhibition of GST-fused CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP	10.1007/s00044-009-9233-5
Sf9	IC₅₀	170 nM Compound: roscovitine, CYC202, seliciclib	Inhibition of human recombinant CDK2/Cyclin E expressed in baculovirus infected sf9 cells using histone H1 as substrate Inhibition of human recombinant CDK2/Cyclin E expressed in baculovirus infected sf9 cells using histone H1 as substrate	[PMID: 23829517]
Sf9	IC₅₀	180 nM Compound: Roscovitine	Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate	[PMID: 22770608]
Sf9	IC₅₀	2.69 μM Compound: 24, CYC202, Seliciclib	Inhibition of His-6-tagged recombinant human CDK1/cyclinB1 expressed in baculovirus-infected sf9 cells by liquid scintillation counting in presence of [gamma-32P]ATP Inhibition of His-6-tagged recombinant human CDK1/cyclinB1 expressed in baculovirus-infected sf9 cells by liquid scintillation counting in presence of [gamma-32P]ATP	[PMID: 24417566]
SH-SY5Y	IC₅₀	16.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTS reduction assay Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTS reduction assay	[PMID: 19128055]
SH-SY5Y	IC₅₀	17 μM Compound: Ros, Seliciclib	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTS reduction assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTS reduction assay	[PMID: 22982525]
SH-SY5Y	IC₅₀	17.4 μM Compound: (R)-roscovitine	Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS assay	[PMID: 23218601]
SH-SY5Y	IC₅₀	17.5 μM Compound: 8a, (R)-roscovitine	Antiproliferative activity against human SH-SY5Y cells assessed as survival after 48 hrs by MTS reduction assay Antiproliferative activity against human SH-SY5Y cells assessed as survival after 48 hrs by MTS reduction assay	[PMID: 18698753]
SH-SY5Y	IC₅₀	21 μM Compound: (R)-Roscovitine; Roscovitine	Antiproliferative activity against human SH-SY5Y cells after 2 days by XTT assay Antiproliferative activity against human SH-SY5Y cells after 2 days by XTT assay	[PMID: 30199702]
SH-SY5Y	IC₅₀	41 nM Compound: 2	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by MTS assay	[PMID: 30639897]
SiHa	IC₅₀	2.69 μM Compound: Roscovitine	Cytotoxicity against human SiHa cells by MTT assay Cytotoxicity against human SiHa cells by MTT assay	[PMID: 36325400]
SK-MEL-2	GI₅₀	15.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SK-MEL-5	GI₅₀	10 μM Compound: (R)-roscovitine	Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SK-OV-3	GI₅₀	35.7 μM Compound: Roscovitine	Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 21080703]
SK-OV-3	GI₅₀	79.4 μM Compound: (R)-roscovitine	Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SNB-75	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SNU-638	IC₅₀	9.77 μM Compound: Roscovitine	Antiproliferative activity against human SNU638 cells after 3 days by SRB assay Antiproliferative activity against human SNU638 cells after 3 days by SRB assay	[PMID: 20361800]
SR	GI₅₀	5.01 μM Compound: (R)-roscovitine	Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay	[PMID: 19128055]
SW-620	GI₅₀	79.4 μM Compound: (R)-roscovitine	Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
T47D	GI₅₀	16.8 μM Compound: (R)-roscovitine	Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay	[PMID: 19128055]
TK-10	GI₅₀	63.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
U-251	GI₅₀	50.1 μM Compound: (R)-roscovitine	Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
U-266	IC₅₀	17.93 μM Compound: CYC202, R-roscovitine	Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay	[PMID: 15958589]
UACC-62	GI₅₀	7.9 μM Compound: (R)-roscovitine	Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
UO-31	GI₅₀	12.6 μM Compound: (R)-roscovitine	Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay	[PMID: 19128055]
WI-38	IC₅₀	24.12 μM Compound: Roscovitine	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32773088]

体外研究
(In Vitro)

(R)-Roscovitine (Seliciclib) 对某些依赖细胞周期蛋白的激酶表现出高效率和高选择性。使用 25 种高度纯化的激酶（包括蛋白激酶 A、G 和 C 异构体、肌球蛋白轻链激酶、酪蛋白激酶 2、IR 酪氨酸激酶、c-src、v-abl）研究了 Seliciclib 的激酶特异性。大多数激酶不会被 (R)-Roscovitine 明显抑制。只有 Cdc2、Cdk2 和 Cdk5 受到显著抑制（IC₅₀ 值分别为 0.65、0.7 和 0.2 μM）。Cdk4k 和 Cdk6 被 (R)-Roscovitine 抑制得非常弱（IC₅₀>100 μM）。细胞外调节激酶 erk1 和 erk2 受到抑制，IC₅₀ 分别为 34 μM 和 14 μM。(R)-Roscovitine 抑制哺乳动物细胞系的增殖，平均 IC₅₀ 为 16 μM^[1]。
(R)-Roscovitine (Seliciclib) 可降低 CDK5 和 p35 水平，上调 E-cadherin，但下调 Vimentin 和 Collagen IV。此外，(R)-Roscovitine 可抑制高糖培养的 NRK52E 细胞迁移和侵袭的能力^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

与正常对照相比，(R)-Roscovitine (Seliciclib) 下调磷酸化的 ERK1/2 和 PPARγ，同时增加 E-钙粘蛋白，但减少波形蛋白和胶原蛋白 IV。相应地，(R)-Roscovitine 可降低糖尿病大鼠的肾小管间质纤维化。(R)-Roscovitine 通过 ERK1/2/PPARγ 通路有效降低糖尿病大鼠的肾小管间质纤维化^[2]。
(R)-Roscovitine (Seliciclib) (16.5 mg/kg) 可显著降低肿瘤生长速度并提高接受治疗的小鼠的存活率。令人惊讶的是，(R)-Roscovitine 治疗导致一只小鼠 (25%) 的肿瘤完全消失；此外，在完成治疗 5 个月后，该小鼠未发现肿瘤复发。接受 (R)-Roscovitine 治疗的小鼠与接受对照治疗的小鼠的体重没有显著差异，两组之间的行为差异也可以忽略不计。这些结果表明，(R)-Roscovitine 可有效用作 HPV+ 头颈癌的选择性肿瘤生长抑制剂^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

354.45

Formula

C₁₉H₂₆N₆O

CAS 号

186692-46-6

性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (282.13 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8213 mL	14.1064 mL	28.2127 mL
5 mM	0.5643 mL	2.8213 mL	5.6425 mL
10 mM	0.2821 mL	1.4106 mL	2.8213 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.05 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); 澄清溶液
方案五

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); 澄清溶液

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.84%

选择批次：

Data Sheet (667 KB) SDS (394 KB)

COA (197 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36. [Content Brief]

[2]. Bai X, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/pparγ pathway. Oncotarget. 2016 Apr 27. [Content Brief]

[3]. Gary C, et al. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016 May 23. [Content Brief]

Cell Assay ^[2]	Rat kidney tubular epithelial cells (NRK52E) are used. CDK5 inhibitor (R)-Roscovitine (Seliciclib) (Ros.; 10 μM) and activator p35 (15 μM), PPARγ agonist BRL 49653 (Rosi.; 50 nM), and ERK1/2 inhibitor U0126 (50 nM) are used to treat NRK52E cells. Cells in each group are treated for 72 hours and then harvested for further analyses^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]^[3]	Rats^[2] Male Sprague Dawley rats (6-8 weeks of age) are given intraperitoneally a single injection of either Streptozotocin (65 mg/kg) diluted in 0.1 M citrate buffer pH 4.5 (diabetic) or citrate buffer (non-diabetic). Plasma glucose concentrations are determined using the glucose oxidase method on a glucose analyzer three days after the injection. Rats with a glucose level over 16.7 mM are considered diabetic and thus included in the study. Plasma glucose level is measured once every week. To investigate the effect of CDK5 inhibition on renal tubulointerstitial fibrosis, Seliciclib (25 mg/kg) is injected peritoneally to diabetic rats every day till sacrifice. DMSO is included as controls. Mice^[3] Exponentially growing UMSCC47 cells are injected subcutaneously into the sacral area of female NUDE mice. Each mouse is inoculated with 2×10⁵ cells in 50% matrigel and 50% PBS at a volume of 100 μL. After tumors reach a measurable size, the mice are given 16.5 mg/kg doses of intraperitoneal Seliciclib or vehicle injections. Body weight, tumor growth, and general behavior are monitored. Tumor volumes are measured every 3 days. Mice are sacrificed when the tumor exceeded a size of 0.5cm³. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Meijer L, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36. [Content Brief] [2]. Bai X, et al. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via erk1/2/pparγ pathway. Oncotarget. 2016 Apr 27. [Content Brief] [3]. Gary C, et al. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 2016 May 23. [Content Brief]

(R)-Roscovitine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8213 mL	14.1064 mL	28.2127 mL	70.5318 mL
	5 mM	0.5643 mL	2.8213 mL	5.6425 mL	14.1064 mL
	10 mM	0.2821 mL	1.4106 mL	2.8213 mL	7.0532 mL
	15 mM	0.1881 mL	0.9404 mL	1.8808 mL	4.7021 mL
	20 mM	0.1411 mL	0.7053 mL	1.4106 mL	3.5266 mL
	25 mM	0.1129 mL	0.5643 mL	1.1285 mL	2.8213 mL
	30 mM	0.0940 mL	0.4702 mL	0.9404 mL	2.3511 mL
	40 mM	0.0705 mL	0.3527 mL	0.7053 mL	1.7633 mL
	50 mM	0.0564 mL	0.2821 mL	0.5643 mL	1.4106 mL
	60 mM	0.0470 mL	0.2351 mL	0.4702 mL	1.1755 mL
	80 mM	0.0353 mL	0.1763 mL	0.3527 mL	0.8816 mL
	100 mM	0.0282 mL	0.1411 mL	0.2821 mL	0.7053 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(R)-Roscovitine186692-46-6Seliciclib CYC202CYC202CYC 202CYC-202CDKCyclin dependent kinaseInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

(R)-Roscovitine (Synonyms: Seliciclib; CYC202)

Customer Review

Other Forms of (R)-Roscovitine:

MCE 顾客使用本产品发表的 31 篇科研文献

(R)-Roscovitine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 CDK 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

(R)-Roscovitine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

(R)-Roscovitine (Synonyms: Seliciclib; CYC202)

Customer Review

Other Forms of (R)-Roscovitine:

(R)-Roscovitine 相关抗体

MCE 顾客使用本产品发表的 31 篇科研文献

(R)-Roscovitine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 CDK 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

(R)-Roscovitine 相关抗体:

摩尔计算器

稀释计算器

(R)-Roscovitine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z